ConsortiumConsortium
consortium teaser

Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms

Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 






EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

AbbVie Deutschland GmbH & Co. KG
Global Pharmaceutical R&D
Knollstrasse
67061 Ludwigshafen
Germany

www.abbvie.de



Participant's Lead


Georg Terstappen Georg Terstappen
Director and Department Head in Neuroscience Discovery 
E-Mail to Georg Terstappen Contact  
 



Institute Presentation


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.


22 AbbVie